MedTrace Logo

Cumulative Irritation Test

NCT00680095 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2019-04-09

No results posted yet for this study

Summary

The purpose of this study is to determine the cumulative irritation potential of the products listed by the Sponsor.

Conditions

  • Onychomycosis

Interventions

DRUG

AN2690

AN2690 Solution, 2.5%, Daily for up to 21 days

DRUG

AN2690

AN2690 Solution, 7.5%, Daily for up to 21 days

DRUG

AN2690

AN2690 Solution, 5.0%, Daily for up to 21 days

OTHER

AN2690 Solution, Vehicle

AN2690 Solution, Vehicle, Daily for up to 21 days

OTHER

Sodium Lauryl Sulfate, 0.5%

Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Purpose
OTHER
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-22
Primary Completion
2007-02-19
Completion
2007-02-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00680095 on ClinicalTrials.gov